Chanhassen-based Alpheus Medical has raised $14 million to advance its development of sonodynamic therapy (SDT) to treat large aggressive brain tumors. Founded just a year ago, in 2021, Alpheus ...

A Chanhassen-based medical company has raised $52 million in its quest to treat an aggressive form of brain cancer. Late last week, Alpheus Medical Inc. announced that it closed its Series B funding ...

Funding will support a randomized Phase 2B study of the novel sonodynamic therapy in patients with newly diagnosed glioblastoma "The complex and diffuse nature of glioblastomas has long hindered ...

"The early clinical results are very encouraging for advancing treatment options in patients with newly diagnosed glioblastoma, a disease with few effective therapies," commented Walter Stummer, ...

After publishing early clinical results of its ultrasound-activated brain tumor therapy this year, Alpheus Medical has raised $52 million in venture capital funding to support a new randomized trial.

The results from their first-in-human study demonstrated that median overall survival was doubled and progression-free survival improved 3-fold The Company's novel sonodynamic therapy platform ...

Please provide your email address to receive an email when new articles are posted on . Ticagrelor was not superior to clopidogrel for reducing periprocedural myocardial necrosis or myocardial injury ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Alpheus’ therapy centers on ...

Patients with high-risk features undergoing elective PCI and treated with the more-potent antiplatelet agent ticagrelor (Brilinta; AstraZeneca) instead of clopidogrel fared no better with respect to ...